Patrick MARCELLINPRESIDENT OF PHC

Happy New Year!

AlbaniaAlgeriaArgentinaArmeniaAustriaAzerbaijanBelgiumBeninBrazilBulgariaCameroonCanadaChinaColombiaCote DivoireCroatiaCzech RepublicDenmarkDominican RepublicEgyptFinlandFrance

Gabon

Georgia

Germany

GreeceGuadeloupeGuyanaHaitiHong KongHungaryIndiaIndonesiaIraqIrelandItalyKorea SoutKuwaitLatviaLebanonLibyaLithuaniaLuxembourgMadagascarMaltaMexicoMongoliaMoroccoMozambiqueNambia

NetherlandsNigeriaNorwayOmanPeruPolandPortugalReunionRomaniaRussiaSaudi ArabiaSenegalSeychellesSlovakiaSloveniaSpainSwedenSwitzerlandTaiwanTunisiaTurkeyUkraineUnited Arab Em.United KingdomUSA

Welcome and thanks to 1000 participants from 75 countries !

9th PHC: Faculty Members

Raymundo PARANAJean-Marie PÉRONAntonello PIETRANGELOStanislas POLAdriana POPESCUVlad RATZIUMario RIZZETTODominique SALMONDidier SAMUELEugene SCHIFFLawrence SERFATYMitchell SHIFFMANPhilippe SOGNIMark SULKOWSKITengiz TSERTSVADZEAlbert TRANChristian TREPOPetr URBANEKDominique VALLAMihai VOICULESCUImam WAKEDYazdan YAZDANPANAHJean-Pierre ZARSKIStefan ZEUZEMKonstantin ZHDANOVFabien ZOULIM

Claire FRANCOZMichael FRIEDAdrian GADANOPere GINESJérôme GOURNAYPhilippe HALFONChristophe HEZODEAndrzej HORBANVasily ISAKOVJi Dong JIAJia-Horng KAOPietro LAMPERTICOVincent LEROYMassimo LEVRERO Jake LIANGMichael MANNSPatrick MARCELLINMichelle MARTINOT-PEIGNOUXPhilippe MATHURINRichard MOREAURami MOUCARI David NELSONDenis OUZANGeorges-Philippe PAGEAUX Raluca PAISGeorgios PAPATHEODORIDIS

Nezam AFDHALTarik ASSELAHPierre BEDOSSANajet BELHADJ BRIKMustapha BENAZZOUZMarc BOURLIEREJean-Pierre BRONOWICKISavino BRUNOMaria BUTIJean-François CADRANELLaurent CASTERAMassimo COLOMBOAntonio CRAXIVictor DE LEDINGHENNabil DEBZIDaniel DHUMEAUXAdrian DI BISCEGLIEVincent DI MARTINOFrançois DURANDAhmed El RAYGamal ESMATRafael ESTEBANEmilie ESTRABAUDPeter FERENCIRobert FLISIAKGraham FOSTER

9th PHC: Scientific Committee

Marc BOURLIERE (France)

Massimo COLOMBO (Italy)

Rafael ESTEBAN (Spain)

Graham FOSTER (UK)

Michael FRIED (USA)

Michael MANNS (Germany)

Confirmed in real life studies…

We have the weapons against HCV we dreamed of!

100% efficacyAll oralShort durationNo resistancePan-genotypicWell tolerated and safeCost...

Amazing acceleration of progress in the last years

20

40

60

80

2002PEG/RIBA

2012TRI

0

70% (G1)

40 - 50%

2016DAAs

≅100%100

All Genotypes

Most of patients around the world have no access to DAAs

170 million HCV patients

Majority of patients treated with IFN/RBV

F0 to F4

F2 to F4

F3 / F4

F4

Restricted indications of DAAs in Europe

How to improve access to therapy?

Enjoy your PHC meeting!

State of the Art Lecture

Chairman :Tarik ASSELAH

The influence of therapy on the burden of hepatitis

Michael FRIED

9th PHC: